WO1993009816A1 - Procede de diagnostic et de traitement du cancer - Google Patents

Procede de diagnostic et de traitement du cancer Download PDF

Info

Publication number
WO1993009816A1
WO1993009816A1 PCT/US1992/009874 US9209874W WO9309816A1 WO 1993009816 A1 WO1993009816 A1 WO 1993009816A1 US 9209874 W US9209874 W US 9209874W WO 9309816 A1 WO9309816 A1 WO 9309816A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
conjugate
cancer
animal
administering
Prior art date
Application number
PCT/US1992/009874
Other languages
English (en)
Inventor
Frederick C. Leung
Darrell R. Fisher
Michael R. Thompson
Scott D. Harvey
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Priority to JP5509460A priority Critical patent/JPH07501332A/ja
Priority to EP93900522A priority patent/EP0614377A1/fr
Priority to CA002123588A priority patent/CA2123588A1/fr
Publication of WO1993009816A1 publication Critical patent/WO1993009816A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Definitions

  • the present invention relates generally to methods for diagnosing and treating cancer.
  • treatment of cancer generally involve the surgical removal of solid tumors, followed by chemotherapy and/or radiotherapy.
  • chemotherapy and/or radiotherapy.
  • One disadvantage of this general approach is that most chemotherapeutic or radiotherapeutic agents are not tumor-cell specific, thus damaging normal tissue during the course of treatment.
  • tumor cells have an increased number of certain cell surface antigens as compared to normal cells. This difference between tumor and normal cells may be exploited in order to more effectively target therapeutic agents to tumor cells. More specifically,
  • targeting agents such as monoclonal antibodies may be used to specifically target and bind to the tumor cells, resulting in the localization and internalization of the ' therapeutic agents.
  • monoclonal antibodies such as the anti-gpl6() antibody for human lung cancer ⁇ see Sugiyama et al., "Selective Growth Inhibition of Human Lung Cancer Cell Lines Bearing a Surface Glycoprotein gp l ⁇ O by 125 I-
  • targeting agents In order to kill tumor cells, targeting agents have been coupled to various chemotherapeutic agents including, among others, ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas toxin, Shigella toxin, and Pokeweed antiviral toxin (see U.S. Patent No. 4,545,985; see also Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immunological Review 62:185-216, 1982; see also Thorpe and Ross, The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates," Immunological Review 62:119-158).
  • chemotherapeutic agents including, among others, ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas toxin, Shigella toxin, and Pokeweed antiviral toxin
  • Beta emitters are disadvantageous because of their low specific activity, low linear energy transfer, low dose rates (allowing for cell repair of radiation damage), damage to surrounding normal tissues, and in some cases the lack of an associated imageable photon (e.g., yttrium-90).
  • the present invention overcomes the disadvantages discussed above, and further provides other related advantages.
  • the present invention provides reagents and methods for detecting and treating cancer.
  • a conjugate of a growth factor and an alpha-emitting radionuclide is provided, the growth factor being capable of specifically binding to a defined population of cancer cells.
  • the growth factor is coupled to the alpha-emitting radionuclide by a linker, such as a short polycarbon compound, to separate the alpha-emitting radionuclide from the growth factor.
  • a linker such as a short polycarbon compound
  • Preferred linkers may be selected from the group consisting of disulfides, dicarboxylic acids, and multi- carbon chain linkers (polycarbons).
  • a particularly preferred linker is hexamethylene diamine.
  • This linker may be coupled to a portion of the growth factor selected from the group consisting of the N-terminus and the C-terminus.
  • the alpha-emitting radionuclide is bound to a sequestering agent, such as, for example, a macrocyclic complexing agent.
  • a sequestering agent such as, for example, a macrocyclic complexing agent.
  • Preferred macrocyclic complexing agents include crown ethers such as a 21-crown-7 or an 18-crown-6 ether.
  • a pharmaceutical composition comprising a conjugate of a growth factor and an alpha-emitting radionuclide, and a pharmaceutically acceptable carrier or diluent, the growth factor being capable of specifically binding to a defined population of cancer cells.
  • the alpha- emitting radionuclide is selected from the group consisting of lead-212/bismuth- 212, bismuth-213/polonium-213, bismuth-212m, bismuth-212, polonium-206, polonium-210, astatine-211, radium-223, radium-224, and actinium-225.
  • a conjugate of a growth factor and non-radioactive iodine is provided, the growth factor being capable of specifically binding to a defined population of cancer cells.
  • Pharmaceutical compositions are also provided, comprising a conjugate of a growth factor and non-radioactive iodine, and a pharmaceutically acceptable carrier or diluent, the growth factor being capable of specifically binding to a defined population of cancer cells.
  • a method for treating cancer in warm-blooded animals comprising administering to a warm ⁇ blooded ammal an effective amount of a conjugate of a growth factor and an alpha-emitting radionuclide, a conjugate of a growth factor and non-radioactive iodine, a conjugate of a growth factor and yttrium-90, or a conjugate of a growth factor and an oxyanion of a metal, the growth factor being capable of specifically binding to a defined population of cancer cells.
  • the above-described method further comprises, prior to the step of administering an effective amount of a conjugate, administering an unlabeled growth factor capable of specifically binding to the defined population of cancer cells, in an amount sufficient to mask growth factor receptors in healthy tissues of the animal.
  • a method for detecting cancer comprising the steps of (a) administering to a warm- blooded animal an effective amount of a conjugate of a growth factor and an alpha-emitting radionuclide, the growth factor being capable of specifically binding to a defined population of cancer cells; and (b) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of cancer.
  • a method for detecting the presence of cancer in warm-blooded animals comprising the steps of (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of a conjugate of the growth factor and a radioactive isotope which emits gamma radiation, and (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of cancer.
  • the radioactive isotope is selected from the group consisting of rhenium-186, technetium-99m, iodine- 131, selenium-75, iodine-123, iodine-125, iodine- 124, indium-Ill, copper-67, radium-223, gold-198, yttrium-90, chromium-51, iron-52, copper-64, gallium-67, gallium-66, gallium-72, galIium-68, zirco ⁇ ium-89, ruthenium-97, lead-203, rhodium-105, rhenium-188, gold-199, astatine-211, bromine-76, bromine-77, fluorine-18, bismuth-206, mercury-197, and mercury-203.
  • a method for diagnosing and treating cancer in warm-blooded animals comprising the steps of (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of conjugate of the growth factor and a radioactive isotope which emits gamma radiation, (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of the cancer, and (d) administering an effective amount of a second conjugate of a growth factor and a radioactive isotope or non- radioactive iodine, such that the cancer is treated.
  • a method for diagnosing and treating cancer in warm-blooded animals comprising the steps of (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of a first conjugate of a growth factor and a radioactive isotope which emits gamma radiation, (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of the cancer, and (d) administering an effective amount of a second conjugate of a growth factor and a cytotoxic metal ion, such that the cancer is treated.
  • the cytotoxic agent is an oxyanion of a metal selected from the group consisting of manganese, technetium, rhenium, chromium, molybdenum, tungsten, vanadium, and tellurium.
  • the cytotoxic agent is an alpha particle emitting radioactive isotope selected from the group consisting of lead-212/bismuth-212, bismuth-213/polonium-213, bismuth-212m, bismuth-212, polonium-206, radium- 224, and actinium-225.
  • the growth factor is selected from the group consisting of epidermal growth factor, transforming growth factor - alpha, fibroblast growth factors, insulin-like growth factor I and II, and nerve growth factor.
  • FIGURE 1 is a table listing various radioactive nuclides which emit alpha-particle radiation.
  • FIGURE 2 schematically illustrates a decay series starting with Cm-243. Radium-223 is a member of this decay series.
  • FIGURE 3 is a graph which illustrates the iodination profile of 1J 1 I to epidermal growth factor.
  • FIGURE 4 is a graph which compares cells treated with 3 I, 131 I- epidermal growth factor, and epidermal growth factor alone.
  • FIGURE 5 is a graph which illustrates the effects of various concentrations of - ⁇ --I-epide ⁇ nal growth factor on A431 cells.
  • FIGURE 6 is a graph which illustrates the effects of various concentrations of 131 I-epidermal growth factor on L cells.
  • FIGURE 7 is a graph which illustrates the effects of various concentrations of non-radioactive iodine-epidermal growth factor on A431 cells.
  • FIGURE 8 is a graph which illustrates the effects of various concentrations of non-radioactive iodine-epidermal growth factor on L cells.
  • the present invention provides reagents for detecting and treating cancer.
  • These reagents generally comprise a conjugate of a growth factor and an alpha-emitting radionuclide, a conjugate of a growth factor and non-radioactive iodine, or any of a number of growth factor conjugates which are described in more detail below, the growth factor being chosen such that it is capable of specifically binding to a defined population of cancer cells.
  • growth factors known to one of ordinary skill in the art may be utilized within the present invention.
  • Representative examples include platelet derived growth factors, transforming growth factor-beta, i ⁇ terleukins (Le., IL-1, IL-2, IL-3, IL- , IL-5, IL-6, IL-7, IL-8, or IL-9), granulocyte-macrophage colony stimulating factor (GMCSF), erythropoietin, tumor necrosis factor, endothelial cell growth factor, platelet basic proteins, capillary endothelial cell growth factor, cartilage-derived growth factor, chondrosarcoma-derived growth factor, retina-derived growth factor, hepatoma derived growth factor, bombesin, and parathyroid hormone.
  • transforming growth factor-beta transforming growth factor-beta
  • i ⁇ terleukins Le., IL-1, IL-2, IL-3, IL- , IL-5, IL-6, IL-7
  • growth factors include epidermal growth factor, transforming growth factor - alpha, fibroblast growth factors, insulin like growth factor I and II, and nerve growth factor.
  • the growth factor should be selected such that it is capable of specifically binding to a defined population of cancer cells which include, for example, preneoplastic cells, premetastatic cells, and tumor cells (both benign and malignant).
  • a defined population of cancer cells may generally be differentiated from normal cells based upon the greater number of growth factor receptors on the cell surface.
  • a growth factor may be defined to be "specifically binding" to a defined population of cancer cells if this population of cells has greater than approximately two times the number of growth factor receptors on its surface as compared to normal cells, and preferably greater than five to ten times the number of growth factor receptors.
  • this difference in the number of growth factor receptors on cancer cells, as compared to normal cells may be exploited in order to more specifically target growth factor conjugates.
  • the number of growth factor receptors on cells in healthy tissue may be determined, and compared to the number of growth factor receptors on cancer cells.
  • unlabeled growth factor capable of specifically binding to a defined population of cancer cells may then be administered in an amount sufficient to mask growth factor receptor sites on the normal cells of healthy tissues, in order to mask the less abundant growth factor receptors on normal cells (if present) prior to the addition of a conjugated growth factor.
  • the number of growth factor receptors on a cell may be readily determined based upon the ability of the cell to bind to the growth factor receptor's substrate.
  • assays such as radioreceptor binding assays which determine the quantity of receptor substrate that binds to a cell over the course of time may be readily utilized to determine the number and type of cell surface receptors (see, for example, Ladda et a ., Anal. Biochem. 93:286-294, 1979).
  • radiolabeled growth factor and membrane preparations isolated from both normal and tumor cells one can readily determine both growth factor receptor number and affinity by a standard competitive binding assay followed by a Scatchard plot analysis (see Scatchard, Anal. N.Y. Acad. Sci. 51:660-612, 1949).
  • the cells of interest e.g., tumor cells
  • the removal of cells may typically be accomplished through surgical procedures, although many other methods may also be utilized, dependent of course on the type of tumor and its location.
  • the tumor cells Once the tumor cells have been removed, they may be maintained in an in vitro culture using conventional media (see, for example, "Media Formulations,” ATCC Cell Lines & Hybridomas, 1988).
  • the number and type of receptors may then be readily determined using methods described above; and a growth factor conjugate selected on the basis of its ability to specifically bind to the tumor cells.
  • the therapeutic (or diagnostic) effectiveness of the growth factor conjugate upon tumor cells may be readily determined by in vitro assays. A representative assay is described below in Examples 1 and 2.
  • growth factor conjugates may be utilized for therapeutic or diagnostic purposes based only upon the known characteristics of certain tumors.
  • certain types of tumors such as human epidermal carcinomas are already well defined, and have been shown to possess abnormally high numbers of epidermal growth factor receptors (see Berger et al., "Epidermal Growth Factor Receptors in Lung Tumors," J. Pathology 152:297-307, 1987; Dotzlaw et al., "Epidermal Growth Factor Gene Expression in Human Breast Biopsy Samples: Relationship to Estrogen and Progesterone Receptor Gene Expression," Cancer Res.
  • an epidermal growth factor conjugate may be readily applied to an epidermal carcinoma without the need to first determine which growth factor to use.
  • Interleukin-2 receptors are expressed by abnormal T cells in patients with certain lymphoid malignancies or autoimmune disorders, but not by resting cells.
  • HTLV-I associated adult T-cell leukemia cells constitutively produce large numbers of IL-2 Tac receptors (see Waldmann, Cancer Surveys 8(4):&91-903, 1989, see also Waldmann, J. Nad. Cane. Inst. S7(12):914-923, 1989).
  • an IL-2 growth factor conjugate may be utilized therapeutically without the need to further classify the malignancy as discussed above.
  • a combination of growth factor conjugates may be utilized based upon the known distribution of tumor types in a given disease. For example, if 80% of human lung tumors express growth factor receptor type A, 15% of human lung tumors express growth factor receptor type B, and the remaining 5% of human lung tumors express growth factor type C; a conjugate may be prepared for the treatment of lung cancer comprising a combination of growth factors conjugates A, B, and C.
  • the growth factor is conjugated to an alpha-emitting radionuclide. Alpha-emitting radionuclides are particularly preferred because they have short range (35-70 ⁇ through solid tissue and 35-700 ⁇ m through lung tissue), and are extremely efficient in killing cells.
  • Preferred alpha-emitting radionuclides include lead-212/bismuth-212, bismuth-213/poIonium-213, bismuth- 212m, bismuth-212, polonium-206, polonium-210, astati ⁇ e-211.
  • Radium-223 is a member of the natural uranium-235 decay series (see Figure 2). It exists naturally in all soils containing uranium and daughter products, but may be found at higher concentrations in uranium mill tailing piles. It may be removed by chemical separation from tailing sands by recovering its predecessor actinium-227.
  • actinium-227 decays naturally to Th-227, which decays naturally to Ra-223 (see Figure 2).
  • Radium-223 may be separated chemically from both Ac-227 and Th-227 by, for example, passing a saline solution over an ion- exchange resin containing the parent radionuclides. The purified salt radium-223 may thus be eluted from the column (see Pilger, UCRL-3877, 1957, University of California Radiation Laboratory, Berkeley, California; M ⁇ ller, "Praparative sense uber Ac-227 und seine Vietnamese Regina area, Sondertik aus Radiochimica Ada 9:181-186, 1968; and Atcher et al., "A Radionuclide Generator for the Production of Pb-211 and its Daughters," J. Radioanal. Nucl. Chem. (Letters) 255(3):215-221, 1989). Radium-223 may also similarly be separated from enriched U-235 stockpiles in which natural radioactive decay has allowed the build-up of Ac-227.
  • radium-223 for medical applications is to start with natural radium-226.
  • radium-226 is first irradiated in a nuclear reactor to produce radium-227.
  • the radium-227 then beta decays to actinium-227.
  • 1.0 curies of radium-226 is irradiated for about 120 days in a hydride assembly (such as the Fast Flux Test Facility, Richland, Washington).
  • This assembly produces neutrons of epithermal energy, optimum for conversion of Ra-226 to Ra-227, which then beta-decays to Ac-227.
  • Other nuclear reactors may, however, also be used to activate Ra-226 to Ra-227. This procedure produces about 9.5 curies of actinium-227.
  • Radium-223 may then be chemically separated from actinium-227 and thorium-227 utilizing methods described above.
  • the growth factor may be conjugated to the alpha-emitting radionuclide by various methods, although it is particularly preferred to bind the alpha-emitting radionuclide to a sequestering agent, for example by positioning the alpha-emitting radionuclide within the sequestering agent, which is in turn coupled by a linker to the growth factor.
  • a variety of diverse organic macrocyclic complexing agents may be used to sequester the alpha-emitting radionuclide including, among others, the following groups: ( 1) spherands, (2) cryptaspherands, (3) cryptands, (4) hemispherands, (5) corrands (modified crown ethers), and (6) podands (acyclic hosts) (see Cram, Science 240:760-67, 1988).
  • these macrocyclic ring compounds are large, somewhat spherical organic compounds which resemble cage structures, and have the ability to hold a heavy radionuclide as a ligand holds a metal ion.
  • the sequestering agent should be selected such that it has both a high affinity and specificity for the alpha-emitting radionuclide as well as a low intrinsic mammalian toxicity. High specificity is essential to avoid displacement by other divalent cations (Mg +2 and Ca +2 ) that are prevalent in physiological fluids. Additionally, the compound should either contain a functional group, or have chemistry which is compatible with the introduction of an appropriate functional group, to allow attachment to the linker.
  • the affinity of the sequestering agent for the alpha-emitting radionuclide is defined by the system energetics as described by Cram (supra). More specifically, as inferred by X-ray crystallographic data of complexed and non-complexed crown ethers, it is believed that the solution conformations of non- complexed ethers lack well-defined cavities with the associated convergently aligned binding sites. During the process of complexation, the crown ether undergoes desolvation and reordering of structure, a process which requires energy.
  • Particularly preferred sequestering agents include 18-crown-6 or 21- crown-7 ethers, including for example modified crown ethers such as dicyclohexano-21-crown-7 (Case and McDowell, Radioact. Radiochem. 7:58, 1990; McDowell et al, Solvent Extr. Ion Exch. 7:377, 1989; for other crown ethers or macrocyclic polyethers, see Pedersen, Science 247:536-540, 1988, U.S. Patent No.
  • Ra 2+ is bound by the etherate oxygen network comprising the interior cavity of the spherical crown-ether molecule. This binding is believed to be pH dependent: Rar complexes with a combination of a proton and smaller Group IA ions for the binding site within the crown cavity.
  • crown ethers may additionally be modified with polarizable functional groups (similar to changes made with closo- and mdo-carboamyl species used in boron-neutron capture therapy), resulting in compounds with greater solubility in aqueous media (see generally, Mizusawa et al., Inorg. C em. 24:1911, 1985). Such changes improve retention of biological specificity after conjugation, and improve the conjugate loading capability of the biological agent. These modifications may be accomplished in tandem with the synthesis of the above-noted crown ethers under appropriate conditions for mild conjugation to the biological delivery system.
  • Additional crown ethers suitable for use within the present invention may be synthesized, or purchased from various sources including, among others, Aldrich Chemical Co. (Milwaukee, Wis.), Fluka Chemical Corp. (Ronkonkoma, N.Y.), and Nisso Research Chemicals, (Iwai Co. Ltd., Tokyo, Japan).
  • Sequestration of the alpha-emitting radionuclide may be achieved by mixing the sequestering agent with a salt of the alpha-emitting radionuclide which has been dissolved in solvent.
  • the particular solvent chosen depends of course on the solubility of the sequestering agent and alpha-emitting radionuclide.
  • Cram and co-workers prepared the sodium complex of a spherand simply by adding excess salt dissolved in acetonitrile to a methylene chloride solution of the spherand (see Cram and Lein, / A . Chem. Soc. 707:3657-3668, 1985).
  • crown ether to sequester or complex with the alpha-emitting radionuclide may be readily determined (see Cox et al., "Rates and Equilibria of Alkaline-Earth-Metal Complexes with Diaza Crown Ethers in Methanol,” Inorg. Chem., 27:4018-4021, 1988; see also Mohite and Khopkar, "Separation of Barium From Alkaline Earths and Associated Elements by Extraction with Dibenzo-18-crown-6 From a Picrate Medium,” Analytica Chimica Ada, 206:363-367, 1988).
  • separation of the complexed and free radionuclide can be accomplished by partitioning between an organic solvent (such as chloroform) and water.
  • the complexed radionuclide will partition into the organic phase, whereas the free radionuclide will reside exclusively in the aqueous phase.
  • chromatographic techniques such as High Performance Liquid Chromatography (HPLC) or Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) may be utilized to separate sequestered radionuclide from the free cation. Once isolated, verification of the molecular architecture may be accomplished.
  • the mode of cation binding can take two forms: ( 1) through external association (i.e., anion/cation pairing without bond formation), or (2) via coordination of the cation to the crown-ether oxygen network.
  • Specificity and strong binding which are preferred for the present applications, are dependent on the latter type of association.
  • Single crystal X-ray diffraction techniques may be used to unambiguously assign the type of interaction for the solid materials, and 17 0, 13 C and *H-NMR may be used to determine the structures of target materials in solution.
  • the alpha-emitting radionuclide is positioned within a sequestering agent which is i turn coupled by a linker to preferably either the amino ("N") or carboxy ("C") terminus of the growth factor.
  • the linker serves to place an inert "spacer" between the biologically active growth factor and the alpha-emitting radionuclide containing complex. This space minimizes steric interactions that may interfere with the growth factor's affinity towards its target.
  • the optimum length of the spacer arm is primarily dependent on the affinity of the growth factor for its target receptor. The higher this affinity, the smaller the relative importance of stearic repulsion between the sequestering agent and the target receptors.
  • linkers may be selected which are suitable for use within the present invention, although presently preferred linkers include disulfides, dicarboxylic acids, polycarbon chains, and modified polycarbon chains. Preferred linkers include hydrocarbon chains which range in length from 4 to 18 carbon atoms. Particularly preferred linkers have at least she methylene units such as hexamethylene diamine.
  • the linker may be attached to any of a number of extraanular functionalities on the sequestering agent, although carboxy and amino functionalities are particularly preferred.
  • a first synthetic step could involve reaction of the sequestering agent with hexamethylene diamine. Subsequent reaction with the C-terminus of the growth factor would complete synthesis of the conjugate.
  • the linker may be coupled to other aspects of the growth factor such as the N-terminus.
  • the sequestering agent may be reacted with succinic anhydride. Subsequent coupling of the linker to the growth factor may then be accomplished through the N-terminus of the growth factor.
  • the sequestering agent may contain an amino functionality.
  • a dicarboxylic acid linker for example, octanedioic acid
  • linkage to the growth factor may be accomplished through the C-terminus.
  • an appropriate functionality is inserted into the sequestering agent.
  • a bromine atom may be incorporated into the appropriate position of an aromatic constituent during synthesis of the macrocyclic compound (see Skowronska-Ptasinska et al., J. Org. Chem 53:5484-91, 1988). Sequential treatment of this compound with n- butyllithium and CO2 yields the carboxy analog:
  • the next step within this embodiment of the invention is the reaction between the functionalized sequestering agent and the linker:
  • the sequestering agent is not immobilized on a rigid support the following by-product may also be produced:
  • chromatographic purification of the reaction mixture to isolate the desired product may be necessary before proceeding.
  • standard semi-preparative chromatographic separations based upon, for example, RP- HPLC or HPLC purification, may be utilized to purify the target compounds from the synthetic mixtures. Products may be detected either by refractive index or by the more sensitive technique of ultraviolet adsorption detection.
  • a chromophoric benzene moiety is incorporated into the sequestering agent to facilitate detection during chromatographic purification.
  • the final reaction within this embodiment involves a similar reaction between the sequestering agent-linker (organic soluble) and the carboxy terminus of the growth factor (water soluble) as summarized below:
  • Solubility incompatibilities may be overcome by use of a 50:50 dimethylformamide:water solvent system (see generally Cooper, The Tools of Biochemistry, Wiley, New York, pp. 234-255, 1977; Cuatrecasas, "Protein Purification by Affinity Chromatography on Polyacrylamide Beads,” J Biol. Chem. 245:3059, 1970; and Cuatrecasas, "Affinity Chromatography of Macromolecules," in Advances in Enzymology, A. Meister (ed.), Wiley, New York, p.29, 1972).
  • the growth factor is conjugated to non-radioactive iodine.
  • non-radioactive iodine may be obtained from many commercial sources, including, for example, Sigma Chemical Co. (St. Louis, Mo.).
  • Various methods which are typically used to label proteins with radioactive iodine may also be utilized to conjugate non-radioactive iodine to the growth factor.
  • iodide normally supplied as Nal
  • I2 oxidized to form I2
  • Representative methods utilizing this technique include the Chloramine T method (Hunter and Greenwood, Nature 794:495-496, 1962), the Iodogen method (see Fraker and Speck, Biochem. Biophys. Res. Commun.
  • an iodinated reagent containing a reactive coupling group may be bound to the protein (see Bolton and Hunter, Biochem. J. 733:529-539, 1973).
  • these growth factor conjugates comprise a growth factor, and a radioactive isotope which emits gamma radiation.
  • radioactive isotopes include rhenium-186, technetium-99m, iodine-131, selenium-75, iodine-123, iodine-125, iodine-124, indium-I l l, copper-67, radium-223, gold-198, yttrium-90, chromium- 51, iron-52, copper-64, gallium-67, gallium-66, gallium-72, gallium-68, zirconium- 89, ruthenium-97, lead-203, rhodium- 105, rhenium-188, gold- 199, astatine-211, bromine-76, bromine-77, fluorine-18, bismuth-206, mercury-197, and mercury-203.
  • the growth factor conjugate comprises a growth factor and a cytotoxic agent.
  • cytotoxic agents include (in addition to the various alpha and gamma emitters discussed above) oxyanions of a metal selected from the group consisting of manganese, technetium, rhenium, chromium, molybdenum, tungsten, vanadium, and tellurium.
  • Conjugated growth factors of the present invention may additionally be purified utilizing a variety of techniques, including among others, column chromatography, HPLC, and RP-HPLC.
  • Conjugates of the present invention may be utilized in various ways. For example, they may be employed in in vitro assays as described below in order to kill specific cells. Additionally, as noted above, the conjugates of the present invention may be utilized for the treatment and detection of cancer in warm ⁇ blooded animals. Many warm-blooded animals may be treated and diagnosed for
  • SUBSTITUTE SHEET cancer including for example, mice, rats, sheep, cows, pigs, monkeys, and humans.
  • a method for treating cancer in warm-blooded animals comprising the step of administering to the animal an effective amount of a conjugate of a growth factor and an alpha-emitting radionuclide, the growth factor conjugate being capable of specifically binding to a defined population of cancer cells.
  • the alpha-emitting radionuclide is selected from the group consisting of lead 212/bismuth-212, bismuth-213/polonium-213, bismuth-212m, bismuth-212, polonium-206, polonium-223, radium-224, and actinium-225.
  • a method for treating cancer in warm-blooded animals comprising administering to the animal an effective amount of a conjugate of a growth factor and yttrium-90, the growth factor conjugate being capable of specifically binding to a defined population of cancer cells.
  • a method for treating cancer in warm-blooded animals comprising the step of administering to the animal an effective amount of a conjugate of a growth factor and an oxyanion of a metal selected from the group consisting of manganese, technetium, rhenium, chromium, molybdenum, tungsten, vanadium, and tellurium, the growth factor conjugate being capable of specifically binding to a defined population of cancer cells.
  • a method for treating cancer in warm-blooded animals comprising the step of administering to the animal an effective amount of a conjugate of a growth factor and non-radioactive iodine, the growth factor conjugate being capable of specifically binding to a defined population of cancer cells.
  • the present invention provides, prior to the step of administering an effective amount of a conjugate as described above, administering an unlabeled growth factor capable of specifically binding to the defined population of cancer cells, in an amount sufficient to mask growth factor receptors in healthy tissues of the animal.
  • administering an unlabeled growth factor capable of specifically binding to the defined population of cancer cells in an amount sufficient to mask growth factor receptors in healthy tissues of the animal.
  • administration of the conjugated growth factor is preceded by the step of administering a "cold" or unlabeled growth factor capable of binding to growth factor receptors in both normal and cancer cells, thereby reducing the number of receptor sites on normal cells available for binding and thus minimizing radiation damage to normal cells.
  • Masking of growth factor receptors may be accomplished in methods for both treating and diagnosing cancer, as described herein.
  • a method for detecting cancer comprising the steps of (a) administering to a warm-blooded animal an effective amount of a conjugate of a growth factor and an alpha- emitting radionuclide, the growth factor being capable of specifically binding to a defined population of cancer cells, and (b) detecting the presence of the conjugate within the warm-blooded animal, and therefrom determining the presence of cancer.
  • conjugates or pharmaceutical compositions as described above may be administered in an effective amount as determined by experimental trials.
  • the presence of the conjugate may be detected by any suitable nuclear medicine radiation camera which detects the requisite particle emissions (e.g., alpha or gamma).
  • a Nuclear Medicine Anger camera fitted with a collimator for the Tc" ⁇ m energy window is particularly preferred.
  • a method for detecting the presence of cancer in warm-blooded animals comprising the steps of (a) administering to the warm-blooded animal an effective amount of a conjugate of a growth factor and an alpha-emitting radionuclide, the growth factor conjugate being capable of specifically binding to a defined population of cancer cells, and (b) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of cancer.
  • a method for detecting the presence of cancer in warm-blooded animals comprising the steps of (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of a conjugate of the growth factor and a radioactive isotope which emits gamma radiation, and (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of cancer.
  • the radioactive isotope is selected from the group consisting of rhenium- 186, technetium-99m, iodine-131, selenium-75, iodine-123, iodine-125, iodine-124, indium- 111, copper-67, radium-223, gold- 198, yttrium-90, chromium- 51, iron-52, copper-64, gallium-67, gallium-66, gallium-72, gallium-68, zirconium- 89, ruthenium-97, lead-203, rhodium-105, rhenium-188, gold-199, astatine-211, bromine-76, bromine-77, fluorine-18, bismuth-206, mercury-197, and mercury-203.
  • a method for diagnosing and treating cancer in warm-blooded animals comprising (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of conjugate of the growth factor and a radioactive isotope which emits gamma radiation, (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of the cancer, and (d) administering an effective amount of a second conjugate of a growth factor and a radioactive isotope or non-radioactive iodine, such that the cancer is treated.
  • a method for diagnosing and treating cancer in warm-blooded animals comprising the steps of (a) administering to the animal an unlabeled growth factor capable of specifically binding to a defined population of cancer cells, in an amount sufficient to mask growth factor receptor sites in healthy tissues of the animal, (b) administering to the animal an effective amount of a first conjugate of a growth factor and a radioactive isotope which emits gamma radiation, (c) detecting the presence and location of the conjugate within the warm-blooded animal and therefrom determining the presence of the cancer, and (d) administering an effective amount of a second conjugate of a growth factor and a cytotoxic metal ion, such that the cancer is treated.
  • the cytotoxic agent is an oxyanion of a metal selected from the group consisting of manganese, technetium, rhenium, chromium, molybdenum, tungsten, vanadium, and tellurium.
  • the cytotoxic agent is an alpha particle emitting radioactive isotope selected from the group consisting of lead-
  • compositions include a conjugate of a growth factor and an alpha-emitting radionuclide, or a conjugate of a growth factor and non-radioactive iodine, or any of the other growth factor conjugates discussed above, along with a pharmaceutically acceptable carrier or diluent.
  • Suitable pharmaceutically acceptable carriers or diluents include neutral buffered saline or saline.
  • the pharmaceutical composition may contain other constituents, including for example buffers, carbohydrates such as glucose, sucrose, or dextrose, preservatives, as well as other stabilizers or excipients.
  • appropriate dosages may be determined by experimental trials, about 5x10 ** " to 5x10* ⁇ * conjugate complexes/70kg of adult weight may be administered assuming a 1:1 ratio of growth factor to the alpha-emitter or non-radioactive iodine. Nevertheless, the amount and frequency of administration will depend of course on many factors such as the condition of the patient, the nature and severity of the disease, as well as the type of cancer being treated.
  • the human cervical epidermoid carcinoma cell line A431 (available from the American Type Culture Collection or "ATCC,” Rockville, Maryland, under accession number CRL 1555) was grown in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum. The cells were harvested by trypsinization with 0.05% trypsin and counted with trypan blue to obtain the number of live cells. A431 cells have approximately 1-2 x 10 6 EGF receptors per cell.
  • Cytotoxicity Assay A431 cells were grown in 6 well cultured plates. Two of the wells were exposed to approximately 500 juCi of radiolabeled EGF ( 131 I-EGF), two of the wells were exposed to free 13 - ⁇ similar to the quantity of 3 -EGF, and the other two wells of A431 cells were exposed to unlabeled EGF similar to the quantity of 1 1 I-EGF. The A431 cells were exposed to the three different treatments for one hour. Cells were washed twice with PBS buffer, and fed with DMEM and cultured for 5 days. The experiment was repeated in four replicate of 6 well plates. At the end of day 5, cells were harvested and counted.
  • FIG. 3 shows that the wells of A431 cells exposed to 131 I-EGF have significantly fewer viable cells as compared to cells exposed to free 131 I or cells exposed to unlabeled EGF.
  • radiolabeled growth factor can be used as a specific cytotoxic agent for human tumor cells which possess high numbers of the growth factor receptor.
  • L cells were prepared as described above in Example 1.
  • L cells are a murine fibroblast cell line which is available from the ATCC under accession number CRL 6362. Unlike A431 cells, L cells have less than 1000 EGF receptors per cell. Cells were grown and harvested as described above in Example IA.
  • Epidermal Growth Factor was iodinated utilizing a procedure identical to that described in Example IB above, except that non-radioactive iodine (Sigma Chemical Co., St. Louis, Mo.) was utilized in place of radioactive iodine.
  • Example IC Cells were prepared and analyzed essentially as described in Example IC. As illustrated in Figures 4 through 7, 13 -EGF has a cytotoxic effect on A431 cells (see Figure 4), but not on cells with low numbers of receptors such as L cells (see Figure 6). When experiments were performed with EGF labeled with non-radioactive iodine, there was a surprising cytotoxic effect similar to that of EGF labeled iJ l ⁇ . Furthermore, the cytotoxic effect did not extend to L cells, indicating that the cytoxic effect was mediated by EGF binding to the cell.
  • mice injected subcutaneously into nude mice.
  • the cells were allowed to grow in the mice for one to two weeks, after which the mice were injected either with or without unlabeled EGF, followed by the injection of 123 I-EGF.
  • the mice were then sacrificed and the percent of injected dose per gram determined in the blood, tumor, muscle, lung, kidney, spleen, liver, intestine, thyroid, urine and stomach. The results of this experiment are set forth below in Tables I and II.
  • Mouse 25-10-1 was blocked with 25 ug native EGF 3 minutes prior to labeled EGF; sacrificed at 10 minutes
  • EGF EGF respectively, 3 minutes prior to labeled EGF; sacrificed at 14 hours.
  • Table II administration of unlabeled growth factor sufficient to mask growth factor receptors in normal healthy tissue, results in the more specific targeting of 123 I-EGF.
  • the invention in its broadest aspect is applicable to the delivery of therapeutic agents to treat other disease conditions; for example, use of growth factor conjugated to a therapeutic agent such as an antibiotic would enhance the efficacy of the therapeutic agent for treating diseases such as rheumatoid arthritis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention décrit des conjugués de facteurs de croissance et de radionucléides alphaémetteurs appropriés pour détecter et traiter le cancer. On décrit également des procédés de traitement du cancer utilisant des conjugués de facteurs de croissance et d'iode non radioactif, des conjugués de facteurs de croissance et d'un oxyanion d'un métal, et des conjugués d'un facteur de croissance et d'un isotope radioactif.
PCT/US1992/009874 1991-11-14 1992-11-16 Procede de diagnostic et de traitement du cancer WO1993009816A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP5509460A JPH07501332A (ja) 1991-11-14 1992-11-16 癌を診断および治療する方法
EP93900522A EP0614377A1 (fr) 1991-11-14 1992-11-16 Procede de diagnostic et de traitement du cancer
CA002123588A CA2123588A1 (fr) 1991-11-14 1992-11-16 Methode de diagnostic et de traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79218191A 1991-11-14 1991-11-14
US07/792,181 1991-11-14

Publications (1)

Publication Number Publication Date
WO1993009816A1 true WO1993009816A1 (fr) 1993-05-27

Family

ID=25156052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009874 WO1993009816A1 (fr) 1991-11-14 1992-11-16 Procede de diagnostic et de traitement du cancer

Country Status (5)

Country Link
EP (1) EP0614377A1 (fr)
JP (1) JPH07501332A (fr)
AU (1) AU3177893A (fr)
CA (1) CA2123588A1 (fr)
WO (1) WO1993009816A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019187A1 (fr) * 1994-01-12 1995-07-20 Amersham International Plc Agents biologiques de ciblage
WO2000040275A2 (fr) * 1999-01-04 2000-07-13 Anticancer Therapeutic Inventions As Preparation et utilisation du radium 223 pour cibler des tissus calcifies a des fins de traitement palliatif contre la douleur, de traitement du cancer des os et de conditionnement de surfaces osseuses
WO2006090232A2 (fr) * 2005-02-22 2006-08-31 Ge Healthcare Limited Complexes de gallium radiomarques, procedes de synthese et d'utilisation pour l'imagerie tep de l'expression du recepteur du facteur de croissance epidermique dans des tumeurs malignes
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
US11273224B2 (en) 2016-04-14 2022-03-15 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-CH2—CH2—O-) units in a ring
US11798700B2 (en) 2018-03-26 2023-10-24 The University Of British Columbia Systems, apparatus and methods for separating actinium, radium, and thorium

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
WO1991001144A1 (fr) * 1989-07-20 1991-02-07 Sandoz Ltd Derives de polypeptide etiquetes
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1991001144A1 (fr) * 1989-07-20 1991-02-07 Sandoz Ltd Derives de polypeptide etiquetes

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019187A1 (fr) * 1994-01-12 1995-07-20 Amersham International Plc Agents biologiques de ciblage
US5705143A (en) * 1994-01-12 1998-01-06 Amersham International Plc Biological targeting agents
WO2000040275A2 (fr) * 1999-01-04 2000-07-13 Anticancer Therapeutic Inventions As Preparation et utilisation du radium 223 pour cibler des tissus calcifies a des fins de traitement palliatif contre la douleur, de traitement du cancer des os et de conditionnement de surfaces osseuses
WO2000040275A3 (fr) * 1999-01-04 2001-06-21 Anticancer Therapeutic Inv Sa Preparation et utilisation du radium 223 pour cibler des tissus calcifies a des fins de traitement palliatif contre la douleur, de traitement du cancer des os et de conditionnement de surfaces osseuses
US6635234B1 (en) 1999-01-04 2003-10-21 Anticancer Therapeutic Inventions As Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
CN1767078B (zh) * 1999-01-04 2012-01-11 抗癌治疗发明公司 制备镭-223的方法、生理学上可接受的制剂和试剂盒
WO2006090232A2 (fr) * 2005-02-22 2006-08-31 Ge Healthcare Limited Complexes de gallium radiomarques, procedes de synthese et d'utilisation pour l'imagerie tep de l'expression du recepteur du facteur de croissance epidermique dans des tumeurs malignes
WO2006090232A3 (fr) * 2005-02-22 2007-04-05 Ge Healthcare Ltd Complexes de gallium radiomarques, procedes de synthese et d'utilisation pour l'imagerie tep de l'expression du recepteur du facteur de croissance epidermique dans des tumeurs malignes
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
US11273224B2 (en) 2016-04-14 2022-03-15 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-CH2—CH2—O-) units in a ring
US11865183B2 (en) 2016-04-14 2024-01-09 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring
US11798700B2 (en) 2018-03-26 2023-10-24 The University Of British Columbia Systems, apparatus and methods for separating actinium, radium, and thorium

Also Published As

Publication number Publication date
JPH07501332A (ja) 1995-02-09
CA2123588A1 (fr) 1993-05-27
EP0614377A1 (fr) 1994-09-14
AU3177893A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
KR860001151B1 (ko) 메탈로티오나인 및 표적탐색용 생물학적 활성 분자의 추적-표지된 접합체의 제조방법
US5679318A (en) Stable therapeutic radionuclide compositions and methods for preparation thereof
Guo et al. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging
US5393512A (en) Stable therapeutic radionuclide compositions and methods for preparation thereof
Deshpande et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice
Fritzberg et al. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer
Kukis et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates
US6680993B2 (en) Method of producing Actinium-225 and daughters
JP2550481B2 (ja) 診断助剤
JPS6270377A (ja) ハプテンで修飾された診断薬および治療薬の抗体コンプレツクス
NL8204108A (nl) In beeld brengen van tumor met radioactief gemerkte monoclonale antilichamen.
Visser et al. Optimal quality 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN
US5059413A (en) Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
AU2005259258A1 (en) Radionuclides for medical use
KR930003312B1 (ko) 메탈로티오네인과 생물학적 활성 분자의 추적-표지 결합체의 제조방법
WO1993009816A1 (fr) Procede de diagnostic et de traitement du cancer
EP0494247B1 (fr) Reduction de la retention non ciblee d'immunoconjugues et leurs metabolites
WO1991004057A1 (fr) Compositions de radionuclides therapeutiques stables et leurs procedes de preparation
Brown et al. Pharmacokinetics of 99mTc-metallothionein-B72. 3 and its F (ab′) 2 fragment
CA2270391C (fr) Procede ex corpore de traitement de cellules sanguines humaines
Hazra et al. Linking radiosilver to monoclonal antibodies reduced by ascorbic acia: Comparison of results with stable silver using gravimetric technique and silver 110-M using radiotracer technique
Guo et al. Targeted Radiopharmaceutical for Tumor Imaging
CA2046621A1 (fr) Utilisation des micro-ondes a des fins immunologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP KP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2123588

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993900522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993900522

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993900522

Country of ref document: EP